Invirsa is developing a small molecule (INV-102) that promotes both DNA repair and the innate immune response to infection and injury. These actions lead to enhanced wound healing associated with reductions in inflammation and viral replication.
INV-102 has demonstrated unprecedented efficacy in animal models of ocular sulfur mustard gas injury. Sulfur mustard is a dangerous chemical weapon, and INV-102 is the first drug to show promise in preventing its long-term effects. There is no current FDA approved therapy for this injury.
In September of 2020, Invirsa received a $29.6M BARDA award ($14.4M plus $15.2M in milestones) to support the clinical development of INV-102 for the treatment of ocular sulfur mustard gas injury and other ocular injuries associated with DNA damage. The award covers development through Phase 3 clinical trials.
Invirsa’s initial commercial focus for INV-102 will be infectious keratoconjunctivitis as there is no treatment for the viral form of this disease which comprises 80% of all cases. INV-102 has demonstrated clear efficacy in animal models of infectious conjunctivitis.
INV-102 has demonstrated unprecedented efficacy in animal models of ocular sulfur mustard gas injury. Sulfur mustard is a dangerous chemical weapon, and INV-102 is the first drug to show promise in preventing its long-term effects. There is no current FDA approved therapy for this injury.
In September of 2020, Invirsa received a $29.6M BARDA award ($14.4M plus $15.2M in milestones) to support the clinical development of INV-102 for the treatment of ocular sulfur mustard gas injury and other ocular injuries associated with DNA damage. The award covers development through Phase 3 clinical trials.
Invirsa’s initial commercial focus for INV-102 will be infectious keratoconjunctivitis as there is no treatment for the viral form of this disease which comprises 80% of all cases. INV-102 has demonstrated clear efficacy in animal models of infectious conjunctivitis.
Location: United States, Ohio, Columbus
Employees: 1-10
Total raised: $8.22M
Investors 3
Funding Rounds 2
| Date | Series | Amount | Investors |
| 15.06.2023 | Series B | $7.7M | Rev1 Ventu... |
| 07.11.2017 | Seed | $520K | - |
Mentions in press and media 7
| Date | Title | Description |
| 15.06.2023 | Invirsa Closes $7.7M Series B Financing | Invirsa, a Columbus, OH-based clinical-stage pharmaceutical company, raised $7.7M in Series B funding. The round was led by CincyTech, with participation from Rev1 Ventures, JobsOhio Growth Capital Fund, and JumpStart Ventures. The company ... |
| 15.06.2023 | CincyTech leads $7.7M round for Columbus-based pharma startup Invirsa | - |
| 14.06.2023 | Invirsa Completes $7.7M Series B Financing | COLUMBUS, OH, Invirsa, a privately held, clinical-stage pharmaceutical company, announced the closing of a $7.7 million Series B financing. >> Click here for more funding data on Invirsa >> To export Invirsa funding data to ... |
| 07.11.2017 | Invirsa Secures $520K in Seed Funding | Invirsa, a Columbus, Ohio-based pharmaceutical company developing a new line of attack against common infectious diseases, closed $520k in seed funding. The round was led by Rev1 Ventures. The company intends to use the funds to bring INV-1... |
| - | Invirsa | - |
| - | Invirsa: Clinical-Stage Pharmaceutical Company Secures $7.7 Million | Invirsa – a privately held, clinical-stage pharmaceutical company focused on developing an innovative topically administered eyedrop formulation INV-102 for ocular conditions associated with DNA damage – announced the closing of a $7.7 mill... |
| - | Manage your consent preferences CincyTech leads $7.7M round for Columbus-based pharma startup Invirsa | - |